Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  BioPharma  /  Bioalliance Pharma richting € 8 in 2014 ? Heden; € 4,25.

Ontvang nu dagelijks onze kooptips!

word abonnee

BioPharma« Terug naar discussie overzicht

Bioalliance Pharma richting € 8 in 2014 ? Heden; € 4,25.

442 Posts
Pagina: «« 1 ... 12 13 14 15 16 ... 23 »» | Laatste | Omlaag ↓
  2. Stif 14 april 2014 19:06
    2014/04/14 | 06:11 BioAlliance Pharma kondigt nieuwe positieve aanbeveling voor de Fase III Livatag ® in primaire leverkanker door het Comite van onafhankelijke deskundigen BioAlliance Pharma SA (Euronext Paris - BIO), bedrijf gespecialiseerd in de ontwikkeling van geneesmiddelen voor zeldzame ziekten in de oncologie innovatie, heeft vandaag aangekondigd dat het Comite van onafhankelijke deskundigen (Data Safety Monitoring Board, DSMB) verantwoordelijk voor het toezicht tolerantie in de fase III herbeleven, ontmoet vandaag voor de vierde keer en gaf een nieuwe positieve aanbeveling voor verdere testen zonder modificatie. De studie protocol voorziet in het bijeenroepen van een internationale commissie van onafhankelijke deskundigen om de gegevens te bekijken tolerantie Livatag ® om de veiligheid van patiënten en om de zes maanden en / of na 75 patiënten werden behandeld te verzekeren. Voor de vierde keer sinds november 2012, de DSMB unaniem aanbevolen voortzetting van de studie zonder wijziging, naar aanleiding van de gunstige analyse van de dataset tolerantie Livatag ®, en dus het goede veiligheidsprofiel van bevestigde product. herbeleven, internationale fase III gerandomiseerde trial, ontworpen om de doeltreffendheid van Livatag demonstreren ® op de overleving bij ongeveer 400 patiënten met hepatocellulair carcinoom (primaire leverkanker) na falen of intolerantie voor sorafenib. Tot op heden, een quarantaine centra zijn geopend in Europa en meer dan 25% van de patiënten werden gerekruteerd in lijn met de planning. De Europese inzet testen blijft en opening studie centra in de Verenigde Staten is aan de gang, na het verkrijgen van het groene licht door de Food and Drug Administration in december vorig jaar. Het einde van werving is gepland voor eind 2015 en 2016 pagina Einde. "Elke nieuwe aanbeveling van onze commissie van deskundigen - nu die meer dan 25% van de patiënten gerekruteerd - versterkt de tolerantie analyse van Livatag ®" zegt Judith Greciet, CEO van BioAlliance Pharma. "Deze positieve beoordeling is een zeer belangrijke kwestie voor deze blockbuster voor de Vennootschap. Het goede veiligheidsprofiel van Livatag ® is een bepalende factor in de algemene beoordeling van het geneesmiddel ontwikkelde een zeldzame vorm van kanker waartegen er weinig of geen therapeutisch alternatief bestaat en vertegenwoordigt een potentiële verkoop geschat op bijna 800 miljoen. "
  4. [verwijderd] 15 april 2014 19:14
    Alle klinische vooruitgang en partners Loramyc, Sitavig, Valdive, Livatag lopen allemaal als gepland.

    Straks rust in de tent, en dan gaan de fransen weer gestaag omhoog.
    Ik denk persoonlijk dat de Amerikanen weer snel komen snoepen in Frankrijk.
    Ik ben erg benieuwd hoe Bioalliance, Nano, Cardio, Adocia, Innate en Genfit er in december voorstaan.
    Vooral Cardio zou wel eens hard kunnen excelleren, naar mijn verwachting gaan die wereldleider worden in cardiologie met haar therapie.
    Bioalliance blijft voor mij de mooiste, alleen niet de meest rendabele voor de kt en mt.
  5. [verwijderd] 16 april 2014 08:37
    BioAlliance Pharma and Topotarget Enter into Merger Agreement to Create a Leading Orphan Oncology Company

    Combined company expected to have increased scale and a highly complementary pipeline of late-stage products addressing significant unmet medical needs --

    -- Topotarget shareholders will receive 2 new BioAlliance Pharma ordinary shares for every 27 Topotarget shares that they own, which implies approximately a 1/3 ownership for Topotarget shareholders and approximately a 2/3 ownership for BioAlliance Pharma shareholders --

    -- BioAlliance Pharma is listed on Euronext Paris and application will be made for a dual listing on NASDAQ OMX Copenhagen --

    Regulatory News:

    BioAlliance Pharma SA (Paris:BIO), an innovative company specialized in the development of drugs within orphan oncology diseases, and Topotarget A/S (NASDAQ OMX - TOPO) a Scandinavian-based biopharmaceutical company, today announced their intention to merge to create a leading orphan oncology company with a highly complementary pipelines of late-stage products addressing significant unmet medical needs. The merger agreement has been unanimously approved by the Boards of Directors of both companies.

    Under the terms of the merger agreement, BioAlliance Pharma will be the continuing company and shares issued by Topotarget will be exchanged to the effect that shareholders of Topotarget will receive 2 newly issued shares in BioAlliance Pharma for each 27 Topotarget shares held, resulting in shareholders of Topotarget owning approximately 1/3 of the shares in the merged company, while existing shareholders of BioAlliance Pharma will hold approximately 2/3.

    www.bioportfolio.com/news/article/189...
  6. [verwijderd] 16 april 2014 08:38
    Highlights of Transaction1:

    The merger of the two biopharmaceutical companies creates a leading orphan oncology company with a highly complementary pipeline of late-stage targeting genuine unmet medical needs
    The total market for orphan oncology drugs exceeds USD ~45 billion in 2013 and is expected to reach USD ~80 billion in 2018. The overall unmet medical need is significant and new rare (or orphan) diseases are continuously discovered
    The new entity will be supported by a highly complementary pipeline of late-stage products with several significant value-creating events anticipated in both the short and medium term, and will benefit from operational efficiencies, combined knowledge-sharing, and a diversified revenue stream driving growth
    Topotarget’s primary product, belinostat, is a novel pan-HDAC (histone deacetylase) inhibitor with more than 1,100 patients treated
    Belinostat is in a pre-registration phase with the FDA for the treatment of relapsed or refractory PTCL (peripheral T-cell lymphoma). Following the assignment of a Prescription Drug User Fee Act, the expected date for an approval is August 9, 2014. The approval would trigger a milestone cash payment of USD 25 million from Topotarget’s US partner, Spectrum Pharmaceuticals as well as a double-digit royalty of sales going forward
    The compound has potential for being explored into other rare cancer indications within hematology and solid tumors. Topotarget holds the exclusive rights outside North America and India.
    BioAlliance Pharma has two products in late-stage development
    Livatag® is currently in a pivotal phase III clinical trial in primary liver cancer, with potential estimated sales of 800 million euros and patent protection until 2032
    Validive®, the second most advanced product of BioAlliance Pharma’s orphan oncology program, was granted Fast Track Designation by the FDA for the prevention and treatment of oral mucositis induced by anticancer treatments in January 2014 and preliminary data from a large international phase II trial are expected in Q4 2014
    The merger will result in a broadened shareholder base with increased market capitalization, and a strengthened value proposition for US and European based investors
    The combined company will be under the leadership of an experienced management team and supervised by a highly skilled international Board of Directors with extensive pharmaceutical industry experience and proven track record
    The merger agreement is endorsed by the two largest institutional shareholders of both companies – in the case of BioAlliance Pharma by Financière de la Montagne and Idinvest Partners, representing 18.8% of the share capital of BioAlliance Pharma and in the case of Topotarget by HealthCap funds and HBM Healthcare Investments, representing 12.6% of the non-diluted share capital of Topotarget – who have agreed to vote in favor of the merger proposal at the upcoming extraordinary general meetings of the respective companies
  7. [verwijderd] 16 april 2014 08:38
    Patrick Langlois, Chairman of the Board of Directors of BioAlliance Pharma, said: “Merging with Topotarget is a major milestone for BioAlliance Pharma. This transaction will result in a new and true leader in orphan oncology. I am confident that, under the leadership of Judith Greciet, the new entity will unleash its full potential and create value for our shareholders.”

    Judith Greciet, Chief Executive Officer of BioAlliance Pharma, said:
    “The merger with Topotarget will strengthen and diversify our position in rare oncology diseases. Topotarget is managed by a highly-experienced team of executives, and the merger will enable both teams to combine their respective expertise to create a new company with a robust and innovative pipeline that is primed for success. It is a unique and timely opportunity to develop an orphan oncology portfolio, which addresses a wider range of life-threatening medical conditions, while creating value for our shareholders”
    .

    Bo Jesper Hansen, Chairman of the Board of Directors Topotarget, said: "Following an extensive strategic review I am confident that we have found the best solution for our shareholders and I am very pleased to see their support as well as the support from BioAlliance Pharma’s largest shareholders. It demonstrates that it is a “meeting of similar minds” with a shared vision of creating an immediately leading orphan oncology company with a strong patient focus”.

    Anders Vadsholt, CEO of Topotarget, said: “The positioning of BioAlliance Pharma, their late stage assets and expertise makes BioAlliance Pharma a perfect fit as a company to merge with, allowing the acceleration of belinostat development in several new orphan oncology indications by leveraging on both team’s synergistic expertise. We are confident that this merger will deliver to our shareholders the best possible value and the opportunity to jointly shape a dynamic new player in the orphan oncology market.”
  8. [verwijderd] 16 april 2014 08:39
    Key transaction terms

    Shares issued by Topotarget will be exchanged to the effect that shareholders of Topotarget will receive 2 newly issued shares in the continuing company, BioAlliance Pharma, for 27 Topotarget shares held, resulting in shareholders of Topotarget owning approximately 1/3 of the shares in the merged company, while existing shareholders of BioAlliance Pharma will hold approximately 2/3
    The merger will be structured as a tax exempt cross-border merger in accordance with Danish, French, and EU legislation
    The merger proposal is, among others, subject to approval at extraordinary general meetings which are expected to be held on June 27, 2014 for Topotarget and on June 30, 2014 for BioAlliance Pharma
    All equity warrants issued by Topotarget (including any warrants not yet vested) will be accelerated and thereby allow the holders of such warrants to exercise their warrants during a period to be determined shortly (those non-exercised will be forfeited)
    The merger is expected to be completed in July/August 2014
    BioAlliance Pharma, listed on Euronext Paris, will apply for a dual listing of its shares at NASDAQ OMX Copenhagen
    Further details on the merger features and terms thereof will be given on or about the time of the calling for the extraordinary general meetings expected on May 26, 2014. Any decision to participate in the merger should be based on the full documentation, including a registered prospectus (Document E) and a merger plan, to be published ahead of the general meetings.
    Management and Corporate Governance following completion of the merger

    The combined company will be led by Judith Greciet, Chief Executive Officer of BioAlliance Pharma
    Mr. Patrick Langlois, will continue to serve as chairman of the Board of Directors of BioAlliance Pharma. Mr. Bo Jesper Hansen, current Chairman of the Board of Topotarget and Mr. Per Samuelsson, HealthCap funds, current member of the Board of Directors of Topotarget are expected to be appointed as members of the Board of Directors of BioAlliance Pharma
    Expected indicative timetable

    May 22, 2014 Meeting of the Boards of Directors to approve final merger documentation, following exercise of Topotarget warrants
    Press release / company announcement on final terms of the merger
    May 23/27, 2014 Filing of final merger plan with French and Danish authorities (post-exercise period of the Topotarget equity warrants)
    Clearance statement (enregistrement) on merger prospectus (Document E) from French regulator and passport of merger prospectus to Denmark
    Calling for the Extraordinary General Meetings
    June 27, 2014 Extraordinary General Meeting of Topotarget to approve merger
    June 30, 2014 Extraordinary General Meeting of BioAlliance to approve merger
    July/August 2014 Completion of the merger
  9. [verwijderd] 16 april 2014 08:39
    Advisors

    Centerview Partners and Nordea acted as financial advisors to BioAlliance Pharma in connection with the merger. Altana and Bech Bruun acted as legal counsel to BioAlliance Pharma. EY and Grant Thornton acted as BioAlliance Pharma’s advisors on auditing and accounting aspects, and Arsene Taxand and Bech-Bruun acted as advisors on tax aspects. Finally, Brunswick acted as PR advisor.

    ABG Sundal Collier acted as financial advisor to Topotarget in connection with the merger.

    Back Bay Life Science Advisors, acted as scientific advisor to Topotarget. Kromann Reumert and Dechert acted as legal counsel to Topotarget. PWC acted as Topotarget’s advisor on auditing, accounting and tax aspects. Finally, Impact Communications acted as PR advisor.

    Conference calls details

    Analysts and investors conference call

    Judith Greciet, Chief Executive Officer of BioAlliance Pharma and Patrick Langlois, Chairman of the Board of Directors of BioAlliance Pharma, jointly with Anders Vadsholt, Chief Executive Officer of Topotarget and Bo Jesper Hansen, Chairman of the Board of Directors of Topotarget will comment on this merger and will be available for a webcast to answer questions during a conference call starting today at 10.30 am CET. The call will be held in English.

    To participate in the conference call, you may call the following telephone number, 5 minutes prior to the scheduled start time.

    Participant PIN Code: 11209864#
    UK Access Number: +44 203 139 4830
    France Access Number: +33 2 90 92 09 77
    Denmark Access Number: + 45 82 33 31 47
    US Access Number: +1 718 873 9077

    event.onlineseminarsolutions.com/r.ht...

    The conference call will also be available to a listen-only audio-cast on Topotarget and BioAlliance Pharma’ websites. A replay of the conference call will be available approximately two hours following the conference call on both Topotarget and BioAlliance Pharma’ websites

    Media conference call

    Judith Greciet, Chief Executive Officer of BioAlliance Pharma and Patrick Langlois, Chairman of the Board of Directors of BioAlliance Pharma, will comment on this transaction specifically for the media during a conference call starting at 09:30 am CET today. The conference call will be held in French.

    Participant Code: 019014

    Dial in numbers:

    France: 0821 230 748
    UK: 020 3398 3444
    International: +44 844 4 73 73 73
  10. [verwijderd] 16 april 2014 08:42
    Financial Summary

    As of April 15, 2014 (at market close) BioAlliance Pharma Topotarget
    Number of outstanding shares 20,682,992 143,317,114
    Number of in the money equity warrants
    (there exists no other securities in the
    money giving access to the share capital of
    BioAlliance Pharma and Topotarget)
    1,212,098 3,977,365
    Total number of shares after exercise of all
    in the money equity warrants
    21,895,090 147,294,479
    Stock price (at market close) € 7.16 DKK3.01
    € 0.40
    30-day trading-day VWAP € 8.48 DKK3.14
    € 0.42
    60-day trading-day VWAP € 8.57 DKK3.14
    € 0.42
    90-day trading-day VWAP € 8.18 DKK3.16
    € 0.42
    Market capitalization Diluted
    € 156,768,844
    Non-Diluted
    € 148,090,223
    Diluted
    DKK 443,356,382
    € 59,381,798
    Non-Diluted
    DKK 431,384,513
    € 57,778,323
    Exchange Ratio 2 BioAlliance Pharma shares for 27 Topotarget shares
    Note: Financials translated at spot exchange rate as of April 15, 2014.
  17. [verwijderd] 21 april 2014 09:51
    quote:

    Luke666 schreef op 20 april 2014 22:33:

    Bakker gaat over fusie, maar zie hier niet echt iets staan daarover.. ;-)
    Post 16 apr 2014 om 08:37 BioAlliance Pharma and Topotarget Enter into Merger Agreement to Create a Leading Orphan Oncology Company

    Dit is het nieuws wat ook op Bours staat.

  19. [verwijderd] 21 april 2014 18:03
    quote:

    Luke666 schreef op 21 april 2014 17:28:

    Dat is idd wat ik bedoel.. Wat gaat de koers doen morgen?
    Niets, het nieuws is van de 15de. Dus oud nieuws, opening op de 16de was +6% maar gedurende de dag liep de winst terug naar rond 0%. Volgens mij zelfs negatief de dag gesloten. De 17de gesloten op +0,7%.
442 Posts
Pagina: «« 1 ... 12 13 14 15 16 ... 23 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 860,01 -0,62%
EUR/USD 1,0655 +0,11%
FTSE 100 7.895,85 +0,24%
Germany40^ 17.714,20 -0,13%
Gold spot 2.392,50 0,00%
NY-Nasdaq Composite 15.282,01 -2,05%

Stijgers

WDP
+3,12%
Kendrion
+2,92%
EBUSCO...
+2,67%
Vopak
+2,61%
NX FIL...
+2,17%

Dalers

JUST E...
-5,11%
TomTom
-4,68%
Fugro
-4,30%
ASMI
-4,00%
BESI
-3,64%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!